This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ALXN1540

Alexion Pharmaceuticals, Inc.

Drug Names(s): ALXN 1540, ALXN-1540

Description: ALXN1540 is one of the mRNA (messenger RNA) rare disease programs from the Company’s collaboration with Moderna, in patients with Crigler-Najjar Syndrome (CN-1), which is caused by mutations in the UGT1A1 gene.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug